Sue Robinson

1.8k total citations
19 papers, 135 citations indexed

About

Sue Robinson is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Sue Robinson has authored 19 papers receiving a total of 135 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Genetics, 10 papers in Pathology and Forensic Medicine and 7 papers in Hematology. Recurrent topics in Sue Robinson's work include Lymphoma Diagnosis and Treatment (10 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). Sue Robinson is often cited by papers focused on Lymphoma Diagnosis and Treatment (10 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). Sue Robinson collaborates with scholars based in Canada, United States and Italy. Sue Robinson's co-authors include Carolyn Owen, Sean Dolan, Michael J. Kovacs, Chaim Shustik, S. Rubin, Keyue Ding, Marina Djurfeldt, Kenneth S. Wilson, David Walde and Andrew R. Belch and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Sue Robinson

16 papers receiving 131 citations

Peers

Sue Robinson
Grzegorz Charliński Poland
Betty Prine United States
Camila Peña Chile
Habib El‐Khoury United States
Ferran Vall‐Llovera Spain
Lisa Barbarotta United States
Pavlina Konstantinidou Greece
Luay Mousa United States
Rupali Bhave United States
Danielle Leão Cordeiro de Farias Brazil
Grzegorz Charliński Poland
Sue Robinson
Citations per year, relative to Sue Robinson Sue Robinson (= 1×) peers Grzegorz Charliński

Countries citing papers authored by Sue Robinson

Since Specialization
Citations

This map shows the geographic impact of Sue Robinson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sue Robinson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sue Robinson more than expected).

Fields of papers citing papers by Sue Robinson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sue Robinson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sue Robinson. The network helps show where Sue Robinson may publish in the future.

Co-authorship network of co-authors of Sue Robinson

This figure shows the co-authorship network connecting the top 25 collaborators of Sue Robinson. A scholar is included among the top collaborators of Sue Robinson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sue Robinson. Sue Robinson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Banerji, Versha, Andrew Aw, Nicole Laferriere, et al.. (2024). Management and use of healthcare resources in patients with chronic lymphocytic leukemia initiating venetoclax in routine clinical practice. Leukemia & lymphoma. 65(5). 609–617.
3.
Owen, Carolyn, Versha Banerji, Nathalie A. Johnson, et al.. (2023). Canadian evidence-based guideline for treatment of relapsed/refractory chronic lymphocytic leukemia. Leukemia Research. 133. 107372–107372. 2 indexed citations
4.
Owen, Carolyn, Versha Banerji, Nathalie A. Johnson, et al.. (2023). Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update. Leukemia Research. 125. 107016–107016. 9 indexed citations
5.
Shore, Eliane M., Zahra Goodarzi, Yulia Lin, et al.. (2023). Defining ferritin clinical decision limits to improve diagnosis and treatment of iron deficiency: A modified Delphi study. International Journal of Laboratory Hematology. 45(3). 377–386. 10 indexed citations
6.
Shore, Eliane M., Zahra Goodarzi, Yulia Lin, et al.. (2022). Defining Ferritin Clinical Decision Limits to Improve Diagnosis and Treatment of Iron Deficiency: A Modified Delphi Study. Blood. 140(Supplement 1). 11082–11084. 3 indexed citations
7.
Owen, Carolyn, Sue Robinson, Anna Christofides, & Laurie H. Sehn. (2022). A Canadian Perspective: Monoclonal Antibodies for Pre- and Post-Exposure Protection from COVID-19 in Vulnerable Patients with Hematological Malignancies. Current Oncology. 29(6). 3940–3949. 8 indexed citations
8.
9.
Whitehead, Lisa, Sue Robinson, Diana Arabiat, Mark A. Jenkins, & Evalotte Mörelius. (2022). The Report of Access and Engagement With Digital Health Interventions Among Children and Young People: Systematic Review (Preprint).
10.
Stilgenbauer, Stephan, Francesc Bosch, Osman İlhan, et al.. (2021). Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study. British Journal of Haematology. 193(2). 325–338. 7 indexed citations
11.
Assouline, Sarit, Lilian Amrein, Raquel Aloyz, et al.. (2020). IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia. Leukemia & lymphoma. 61(7). 1653–1659. 6 indexed citations
12.
Assouline, Sarit, Shen Li, Christian Gisselbrecht, et al.. (2019). Event-Free Survival As a Surrogate for Overall Survival in Relapsed DLBCL after Autologous Transplant: A Subgroup Analysis of LY.12 and Coral. Blood. 134(Supplement_1). 768–768. 2 indexed citations
13.
Byrd, John C., Amy S. Ruppert, Nyla A. Heerema, et al.. (2018). Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advances. 2(14). 1705–1718. 16 indexed citations
14.
15.
Owen, Carolyn, et al.. (2015). A Canadian Perspective on the First-Line Treatment of Chronic Lymphocytic Leukemia. Clinical Lymphoma Myeloma & Leukemia. 15(6). 303–313. 1 indexed citations
16.
17.
Shustik, Chaim, Andrew R. Belch, Sue Robinson, et al.. (2006). A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. British Journal of Haematology. 136(2). 203–211. 58 indexed citations
18.
19.
Robinson, Sue. (1988). Handling cytotoxic drugs. Nursing Standard. 2(41). 34–35. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Grzegorz Charliński Breakdown of academic impact, for papers by Betty Prine Breakdown of academic impact, for papers by Camila Peña Breakdown of academic impact, for papers by Habib El‐Khoury Breakdown of academic impact, for papers by Ferran Vall‐Llovera Breakdown of academic impact, for papers by Lisa Barbarotta Breakdown of academic impact, for papers by Pavlina Konstantinidou Breakdown of academic impact, for papers by Luay Mousa Breakdown of academic impact, for papers by Rupali Bhave Breakdown of academic impact, for papers by Danielle Leão Cordeiro de Farias
Rankless by CCL
2026